PATIENT Act of 2015
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Mar 13, 2015)
Promoting Access for Treatments Ideal in Enhancing New Therapies Act of 2015 or the PATIENT Act of 2015
This bill amends the Federal Food, Drug, and Cosmetic Act to extend to five years the three-year marketing exclusivity period provided to certain new drugs that include an active ingredient that was already approved by the Food and Drug Administration.
A drug is provided this extended exclusivity period if it is approved for a new indication or use, or the drug has been reformulated or redesigned to:
- promote greater patient adherence to an approved treatment regime,
- reduce the public health risks associated with the drug,
- reduce side effects or adverse events,
- provide benefits to the health-care system, or
- provide other comparable patient benefits.
What just happenedMar 20, 2015
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseMar 13, 2015
- Mar 20, 2015Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Mar 13, 2015IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Mar 13, 2015IntroReferralIntro-H
Introduced in House
- Mar 13, 2015IntroReferral1000
Introduced in House